scholarly journals Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register

2016 ◽  
Vol 59 ◽  
pp. 171-178 ◽  
Author(s):  
J. Lyth ◽  
R. Mikiver ◽  
K. Nielsen ◽  
K. Isaksson ◽  
C. Ingvar
Keyword(s):  
Population Based ◽  
Survival Outcome ◽  
Melanoma Patients ◽  
Prognostic Instrument

scholarly journals Statin use and its effect on all‐cause mortality of melanoma patients: a population‐based Dutch cohort study

2014 ◽  
Vol 3 (5) ◽  
pp. 1284-1293 ◽  
Author(s):  
Elisabeth Livingstone ◽  
Loes M. Hollestein ◽  
Myrthe P. P. Herk‐Sukel ◽  
Lonneke Poll‐Franse ◽  
Arjen Joosse ◽  
...  
Keyword(s):  
Cohort Study ◽  
Population Based ◽  
All Cause Mortality ◽  
Melanoma Patients ◽  
Dutch Cohort ◽  
Statin Use

scholarly journals Diagnosis and clinical management of melanoma patients at higher risk of a new primary melanoma: A population-based study in New South Wales, Australia

2016 ◽  
Vol 58 (4) ◽  
pp. 278-285 ◽  
Author(s):  
Caroline G Watts ◽  
Christine M Madronio ◽  
Rachael L Morton ◽  
Chris Goumas ◽  
Bruce K Armstrong ◽  
...  
Keyword(s):  
Clinical Management ◽  
New South ◽  
New South Wales ◽  
Primary Melanoma ◽  
Population Based ◽  
Population Based Study ◽  
South Wales ◽  
Melanoma Patients

scholarly journals Significantly Inferior Overall and Event Free Survival in Pediatric Oncology Patients with Symptomatic Venous Thrombotic Events As Compared to Those without Symptomatic Venous Thrombotic Events: A Population Based Study from Maritimes, Canada

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 393-393 ◽  
Author(s):  
Zara Forbrigger ◽  
Carol Digout ◽  
Conrad Fernandez ◽  
Mark Bernstein ◽  
Ketan Kulkarni
Keyword(s):  
Pediatric Oncology ◽  
Health Centre ◽  
Population Based ◽  
Survival Outcome ◽  
Rank Test ◽  
Oncology Patients ◽  
Free Survival ◽  
Log Rank Test ◽  
First Relapse ◽  
Diagnosis Date

Abstract Background: Symptomatic venous thrombotic events (sVTE) are a well-recognized complication in pediatric oncology patients. Although data exists on incidence, risk factors and outcome of sVTE, the association of sVTE with survival outcome in pediatric oncology patients has not been previously assessed. The present study was designed to assess the survival outcome in pediatric oncology patients who developed sVTE as compared to those who did not develop sVTE. Aims: To assess the overall survival (OS) and event free survival (EFS) in pediatric oncology patients with and without sVTE. Methods: The Maritimes constitutes the 3 Canadian Provinces of Nova Scotia, New Brunswick and Prince Edward Island (total population = 1.8 million). All pediatric oncology patients from the Maritimes are treated at IWK Health Centre (IWK) in a shared care model with regional provincial hospitals. This provides a population-based cohort. Institutional ethics board approval for this retrospective study was obtained. A database of all pediatric oncology patients treated at the IWK Health Centre from 2000-2015 was created by amalgamating data from (i) pediatric oncology hospital database (ii) Provincial Cancer in Young People registry (iii) pharmacy database and (iv) hospital health records. All pediatric oncology patients who developed sVTE were identified using the above databases. Data from all databases was cross-verified for accuracy and then pooled. Data on patient demographics, diagnosis, date of diagnosis, date of last follow up, date of first relapse, and date of death were extracted. Status of every patient on or up to 31 December 2015 was reviewed. SPSS version 22 was used for statistical analysis. Survival outcome was assessed using the Kaplan Meier method. Survival was reported in complete months. sVTE was defined as radiologically documented VTE with at least one sign/symptom directly associated with VTE. First relapse or death were classified as events for calculation of EFS. Both OS and EFS were calculated from diagnosis of cancer. Results: Forty-seven (5.02±0.01%) of the 936 patients had sVTE. The mean age at diagnosis for sVTE patients was 10.1 years. The gender ratio was male:female= 1.8:1 in patients with sVTE. Central veins were the most common location for sVTE (72.3%, n=34). The underlying cancer diagnosis in patients with sVTE were leukemia (36.2%, n=17), lymphoma (19.1%, n=9), sarcoma (19.1%, n=9), brain tumor (2.1%, n=1) and others (23.4%,n=11). The OS of patients with sVTE was significantly inferior (p<0.001 by log rank test) as compared to those without sVTE (Figure 1). The estimated mean OS of patients with and without sVTE were 133.1 ±33.6 and 163.7 ±4.8 months respectively (p<0.001). The estimated 5 year OS for patients who developed sVTE was significantly inferior (p=0.007 by log rank test) as compared to those without VTE. Of the 47 patients with sVTE, 17 (36.2%) died. In comparison, among patients without sVTE, 133 (15%) died (p=0.001). The EFS of patients with sVTE was significantly inferior (p<0.001 by log rank test) as compared those without sVTE (Figure 2). The estimated mean EFS of patients with and without sVTE were 112.7 ±31 and 148.7 ±5.9 months respectively (p<0.001). Conclusion: In a large population-based cohort, we demonstrate that the survival outcome of pediatric oncology patients with sVTE is inferior as compared to those without sVTE. A plausible explanation is that patients at higher risk for death: poor prognosis/advanced cancers and those with more intense multimodality therapy are more likely to be diagnosed with sVTE. Validation of these findings is necessary, as is a better understanding of the drivers for this association of sVTE with early death and the possible role of thromboprophylaxis in optimizing outcomes. Disclosures No relevant conflicts of interest to declare.

scholarly journals Impact of metformin on survival outcome in ovarian cancer: a nationwide population-based cohort study

2021 ◽  
Vol 32 ◽  
Author(s):  
Jeong-Yeol Park ◽  
Myong Cheol Lim ◽  
Min-Hyun Baek ◽  
Young-Han Park ◽  
Seonok Kim
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Survival Outcome

Survival trends among patients with metastatic melanoma in the United States: A population based study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 9555-9555 ◽  
Author(s):  
Ranju Kunwor ◽  
Mahesh Nepal ◽  
Dominic Ho ◽  
Krishna Bilas Ghimire
Keyword(s):  
United States ◽  
Metastatic Melanoma ◽  
Relative Survival ◽  
The United States ◽  
Population Based ◽  
Age Group ◽  
Significant Survival ◽  
Melanoma Patients ◽  
And Gender ◽  
Registry Database

9555 Background: Ipilimumab was approved by FDA in March 2011 for the treatment of Metastatic Melanoma. We conducted this study to compare survival outcome in patients with Metastatic Melanoma in pre- (1973-2010) and post- (2011-2013) ipilimumab era in the United States using U.S. Surveillance, Epidemiology, and End Result (SEER) registry database. Methods: We selected patients with metastatic melanoma age ≥ 20 years from the SEER database. We used SEER 18 registry database to evaluate relative survival (RS) rate during 1973-2010 and 2011-2013. The RS rate at 1year and 2 year were analyzed for cohorts by age (20-49 years, 50-74 and ≥75 years), race [White, African American (AA), and others] and gender. The RS rates (%) accompany standard error (SE). We used SEER Stat software for statistical analysis. Results: There were a total of 129,362 (106,516 and 22,846 in pre and post ipilimumab era) metastatic melanoma patients, male (n = 71,220), female (n = 58,142), white (n = 121,843), AA (n = 854) other (n = 1,315) reported in the registry. RS in pre vs post-ipilimumab era for age group 20-49 was: 96.50 ± 0.1% vs 97.20 ±0.3%, P = 0.013; and 94.10 ± 0.1% to 95.60 ±0.40, P = 0.0009; for age group 50-74 was: 94.10 ± 0.1% vs 95.30 ± 0.2%, P = 0.0001; and 90.70 ± 0.1%vs 92.90 ± 0.3%, P = 0.0001; and for age group ≥75 was 90.80 ± 0.3% vs 91.40 ± 0.7%, P = 0.23; and 85.0 ± 0.4% vs 88.10 ± 1.0%, P = 0.011 at 1 and 2 years respectively. Overall RS in pre and post ipilimumab era for white population was: 93.83 ± 0.16% vs 94.567 ± 0.4%, P = 0.017; and 90.0 ± 0.2% vs 92.033 ± 0.6%, P = 0.0008 at 1 and 2 years respectively. Similarly RS for AA was: 78.07 ± 2.93% vs 73.33 ± 8.23%, P = 0.37; and 65.87 ± 3.47% vs 65.33 ± 9.73%, P = 0.94; and for other race was: 85.2 ± 2.13% vs 77.97 ± 5.6%, P = 0.04; and 74.43 ± 5.2% vs 69.67 ± 6.7%, P = 0.1 at 1 year and 2 years. Conclusions: Our study showed that younger (20-74 years) patients with metastatic melanoma have improvement in 1 and 2-year RS rates in post ipilimumab era. Subgroup analysis by race showed no improvement in RS in AA and other races patients during this period. There was also no significant survival benefit seen in older (≥ 75 years) patients of all races and gender in post ipilimumab era.

scholarly journals Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan

2013 ◽  
Vol 24 (4) ◽  
pp. 342 ◽  
Author(s):  
Ying-Cheng Chiang ◽  
Chi-An Chen ◽  
Chun-Ju Chiang ◽  
Tsui-Hsia Hsu ◽  
Ming-Chieh Lin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Population Based ◽  
Survival Outcome ◽  
National Population ◽  
Population Based Registry

scholarly journals Effect of Age on Survival Outcome in Operated and Non-Operated Patients with Colon Cancer: A Population-Based Study

PLoS ONE ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. e0147383 ◽  
Author(s):  
ZhongHua Jiang ◽  
XiaoHong Wang ◽  
XueMing Tan ◽  
ZhiNing Fan
Keyword(s):  
Colon Cancer ◽  
Population Based ◽  
Survival Outcome ◽  
Population Based Study ◽  
Effect Of Age
Sign in / Sign up

Export Citation Format

Share Document